成大生物：冻干人用狂犬病疫苗（人二倍体细胞）获得药品注册证书

Core Viewpoint - Chengda Biological (688739.SH) has received a drug registration certificate from the National Medical Products Administration for its lyophilized human rabies vaccine, marking a significant advancement in vaccine development in China [1] Group 1: Product Development - The vaccine is developed using MRC-5 human diploid cells, which are derived from healthy human embryonic lung tissue, ensuring excellent safety, immunogenicity, and durability of immunity [1] - This product is the first in China to include three immunization schedules: "simple 4-dose," "2-1-1," and "5-dose," showcasing its adaptability to various immunization needs [1] Group 2: Market Implications - The approval of the "simple 4-dose" immunization schedule represents a breakthrough in the adaptability of human diploid rabies vaccines in China [1] - The diverse immunization programs allow the vaccine to cater to different exposure levels, time arrangements, and compliance rates, enhancing the overall completion rate of immunization and optimizing post-exposure prevention strategies [1] - The human diploid rabies vaccine possesses differentiated competitive advantages, which will enrich the company's product portfolio and better meet clinical demands [1]